Dr SaiVani Yellampalli
@drsaivani.bsky.social
Assistant professor of Nephrology in Santhiram Medical College, Nandyal
Passionate in Preventive Nephrology and Critical Care Nephrology
Passionate in Preventive Nephrology and Critical Care Nephrology
Reposted by Dr SaiVani Yellampalli
potassium goals and cardiac arrhythmias ?
check out next nephJC
check out next nephJC
Oh, the weather outside is frightful 🥶🥶
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast
POTCAST- K+ Pop and Arrhythmia Drop — NephJC
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
www.nephjc.com
January 27, 2026 at 6:22 AM
potassium goals and cardiac arrhythmias ?
check out next nephJC
check out next nephJC
Yah true potassium is a double edged sword low and high both can cause arrhythmias
Maintain normal potassium
I think this trial might decrease fear of hyper kalemia
#NephJC
Maintain normal potassium
I think this trial might decrease fear of hyper kalemia
#NephJC
January 28, 2026 at 2:26 AM
Yah true potassium is a double edged sword low and high both can cause arrhythmias
Maintain normal potassium
I think this trial might decrease fear of hyper kalemia
#NephJC
Maintain normal potassium
I think this trial might decrease fear of hyper kalemia
#NephJC
Hi I am Dr Sai vani
No COI
Eager to learn potcast trial
# NephJC
No COI
Eager to learn potcast trial
# NephJC
January 28, 2026 at 2:23 AM
Hi I am Dr Sai vani
No COI
Eager to learn potcast trial
# NephJC
No COI
Eager to learn potcast trial
# NephJC
Hi I am Dr Sai vani
No coi
No coi
January 28, 2026 at 2:22 AM
Hi I am Dr Sai vani
No coi
No coi
Reposted by Dr SaiVani Yellampalli
🧬 C3G
APPEAR-C3G or VALIANT?
📉 Proteinuria vs placebo:
🔹 Iptacopan: 35%
🔹 Pegcetacoplan: 67%
🎯 Blocking factor B 🆚 🚫C3
Where would you place your bet today? #nephsky #Medsky @thelancet.com @nejm.org
🦋 join us today on #nephjc
APPEAR-C3G or VALIANT?
📉 Proteinuria vs placebo:
🔹 Iptacopan: 35%
🔹 Pegcetacoplan: 67%
🎯 Blocking factor B 🆚 🚫C3
Where would you place your bet today? #nephsky #Medsky @thelancet.com @nejm.org
🦋 join us today on #nephjc
January 13, 2026 at 3:34 PM
🧬 C3G
APPEAR-C3G or VALIANT?
📉 Proteinuria vs placebo:
🔹 Iptacopan: 35%
🔹 Pegcetacoplan: 67%
🎯 Blocking factor B 🆚 🚫C3
Where would you place your bet today? #nephsky #Medsky @thelancet.com @nejm.org
🦋 join us today on #nephjc
APPEAR-C3G or VALIANT?
📉 Proteinuria vs placebo:
🔹 Iptacopan: 35%
🔹 Pegcetacoplan: 67%
🎯 Blocking factor B 🆚 🚫C3
Where would you place your bet today? #nephsky #Medsky @thelancet.com @nejm.org
🦋 join us today on #nephjc
Reposted by Dr SaiVani Yellampalli
It's 2026!🎉
We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST.
Join us on TWITTER (it will always be Twitter to us).
Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down.
www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025
We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST.
Join us on TWITTER (it will always be Twitter to us).
Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down.
www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025
Top Stories in Nephrology 2025 — NephJC
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
www.nephjc.com
January 3, 2026 at 7:22 PM
Reposted by Dr SaiVani Yellampalli
Feed: "Blog - NephJC"
By: Cristina Adriana Popa on Saturday, January 3, 2026
By: Cristina Adriana Popa on Saturday, January 3, 2026
Top Stories in Nephrology 2025
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
www.nephjc.com
January 4, 2026 at 1:16 AM
Feed: "Blog - NephJC"
By: Cristina Adriana Popa on Saturday, January 3, 2026
By: Cristina Adriana Popa on Saturday, January 3, 2026
Reposted by Dr SaiVani Yellampalli
The LIBERATE-D VA by
@sejalplakhani.bsky.social
Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky
www.nephjc.com/news/liberateva
@sejalplakhani.bsky.social
Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky
www.nephjc.com/news/liberateva
LIBERATE-D: The Visual Abstract — NephJC
In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check ou...
www.nephjc.com
December 15, 2025 at 2:43 PM
The LIBERATE-D VA by
@sejalplakhani.bsky.social
Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky
www.nephjc.com/news/liberateva
@sejalplakhani.bsky.social
Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky
www.nephjc.com/news/liberateva
Reposted by Dr SaiVani Yellampalli
We are discussing LIBERATE-D this week on AKI
www.nephjc.com/news/liberat...
Summary by @msocomd.bsky.social and @sejalplakhani.bsky.social !
#NephJC
www.nephjc.com/news/liberat...
Summary by @msocomd.bsky.social and @sejalplakhani.bsky.social !
#NephJC
Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
www.nephjc.com
December 15, 2025 at 2:30 PM
We are discussing LIBERATE-D this week on AKI
www.nephjc.com/news/liberat...
Summary by @msocomd.bsky.social and @sejalplakhani.bsky.social !
#NephJC
www.nephjc.com/news/liberat...
Summary by @msocomd.bsky.social and @sejalplakhani.bsky.social !
#NephJC
Reposted by Dr SaiVani Yellampalli
1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed the PISCES study 🐟 on the role of fish oil on cardiovascular events in hemodialysis patients. This study was presented at Kidney Week with simultaneous publication, and was as unexpected as a shark attack🦈.
Welcome to #TenPostNephJC
Last #NephJC we discussed the PISCES study 🐟 on the role of fish oil on cardiovascular events in hemodialysis patients. This study was presented at Kidney Week with simultaneous publication, and was as unexpected as a shark attack🦈.
December 12, 2025 at 2:59 PM
1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed the PISCES study 🐟 on the role of fish oil on cardiovascular events in hemodialysis patients. This study was presented at Kidney Week with simultaneous publication, and was as unexpected as a shark attack🦈.
Welcome to #TenPostNephJC
Last #NephJC we discussed the PISCES study 🐟 on the role of fish oil on cardiovascular events in hemodialysis patients. This study was presented at Kidney Week with simultaneous publication, and was as unexpected as a shark attack🦈.
October 29, 2025 at 1:06 AM
Is operational tolerance induction finally safe and feasible for some kidney transplant recipients: A breakthrough to a new horizon? - American Journal of Transplantation www.amjtransplant.org/article/S160...
Is operational tolerance induction finally safe and feasible for some kidney transplant recipients: A breakthrough to a new horizon?
Bringing concepts of tolerance induction to clinical reality through advanced-phase
randomized controlled trials (RCTs) has been an Achilles heel in organ transplantation
since Owen1 and Billingham et...
www.amjtransplant.org
September 29, 2025 at 4:53 PM
Is operational tolerance induction finally safe and feasible for some kidney transplant recipients: A breakthrough to a new horizon? - American Journal of Transplantation www.amjtransplant.org/article/S160...
Hi, I am Dr Sai vani from India good morning everyone
September 3, 2025 at 1:19 AM
Hi, I am Dr Sai vani from India good morning everyone
Reposted by Dr SaiVani Yellampalli
Join us for #NephJC 👇🏻
Join us 9/2/25 at 9pm EST.
We will discuss the use of spironolactone in patients on dialysis to prevent t cardiovascular outcomes and heart failure hospitalizations.
Invite your friends. #NephJC #NephSky
www.nephjc.com/news/achieve
We will discuss the use of spironolactone in patients on dialysis to prevent t cardiovascular outcomes and heart failure hospitalizations.
Invite your friends. #NephJC #NephSky
www.nephjc.com/news/achieve
In ESRD is spironolactone an overACHIEVEr? — NephJC
This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?
www.nephjc.com
September 2, 2025 at 2:27 AM
Join us for #NephJC 👇🏻
After reading the initial chapter the factors helped tuberculosis to conquer us in initial days is very disheartening, it is the story of many countries not the only henry
August 20, 2025 at 1:24 AM
After reading the initial chapter the factors helped tuberculosis to conquer us in initial days is very disheartening, it is the story of many countries not the only henry
Hi , I am Dr Saivani
From India, we often come across the Tuberculosis in pulmonary and extra pulmonary forms, in our day to day clinical practise.
I have thouroughly enjoyed reading the book of Everything tuberculosis
#Nephjc
From India, we often come across the Tuberculosis in pulmonary and extra pulmonary forms, in our day to day clinical practise.
I have thouroughly enjoyed reading the book of Everything tuberculosis
#Nephjc
August 20, 2025 at 1:17 AM
Hi , I am Dr Saivani
From India, we often come across the Tuberculosis in pulmonary and extra pulmonary forms, in our day to day clinical practise.
I have thouroughly enjoyed reading the book of Everything tuberculosis
#Nephjc
From India, we often come across the Tuberculosis in pulmonary and extra pulmonary forms, in our day to day clinical practise.
I have thouroughly enjoyed reading the book of Everything tuberculosis
#Nephjc
July 23, 2025 at 2:04 AM
Reposted by Dr SaiVani Yellampalli
On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
Mind The Gap: When eGFR Creatinine and Cystatin C Disagree — NephJC
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
www.nephjc.com
July 21, 2025 at 11:31 AM
On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
July 9, 2025 at 1:26 AM
Hi an interesting discussion on flozins n finerenone in confident trial
July 9, 2025 at 1:14 AM
Hi an interesting discussion on flozins n finerenone in confident trial
Reposted by Dr SaiVani Yellampalli
T0a:
CKD is rising, yet still flies under the radar—underdiagnosed, undertreated, and underserved
Awareness helps, but outcomes won’t improve without scalable solutions that move beyond education and into action
#NephJC
CKD is rising, yet still flies under the radar—underdiagnosed, undertreated, and underserved
Awareness helps, but outcomes won’t improve without scalable solutions that move beyond education and into action
#NephJC
June 25, 2025 at 1:07 AM
T0a:
CKD is rising, yet still flies under the radar—underdiagnosed, undertreated, and underserved
Awareness helps, but outcomes won’t improve without scalable solutions that move beyond education and into action
#NephJC
CKD is rising, yet still flies under the radar—underdiagnosed, undertreated, and underserved
Awareness helps, but outcomes won’t improve without scalable solutions that move beyond education and into action
#NephJC